{"id":"NCT02741596","sponsor":"Shire","briefTitle":"Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE","officialTitle":"HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-26","primaryCompletion":"2019-10-31","completion":"2019-10-31","firstPosted":"2016-04-18","resultsPosted":"2020-05-11","lastUpdate":"2021-06-08"},"enrollment":212,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"DX-2930","otherNames":[]},{"type":"DRUG","name":"DX-2930","otherNames":[]}],"arms":[{"label":"Rollover Participants","type":"EXPERIMENTAL"},{"label":"Non-rollover Participants","type":"EXPERIMENTAL"}],"summary":"This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From start of the study up to follow-up (Day 952)","effectByArm":[{"arm":"Rollover Participants","deltaMin":105,"sd":null},{"arm":"Non-rollover Participants","deltaMin":101,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":43,"countries":["United States","Canada","Germany","Italy","Jordan","Puerto Rico","United Kingdom"]},"refs":{"pmids":["39128590","37028510","36153561","34287942","29043014"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":109},"commonTop":["Injection site pain","Viral upper respiratory tract infection","Upper respiratory tract infection","Headache","Injection site erythema"]}}